CIK 0000899923
- Accelerated filer
MYRIAD GENETICS INC
Sign in to watch- Ticker
- MYGN
- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 870494517
- Phone
- +1 801-584-3600
- Business address
- 322 NORTH 2200 WEST, SALT LAKE CITY, UT, 84116
- Former names
- MYRIAD GENETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-03-24 | Lambert Nicole President, Myriad Oncology, | Grant or award | +29,556 | 135,768 | ||
| 2021-03-24 | Riggsbee Richard Bryan Chief Financial Officer | Grant or award | +32,774 | 339,925 | ||
| 2021-03-24 | Hart Jayne B. Chief People Officer | Grant or award | +13,326 | 80,128 | ||
| 2021-03-24 | Verratti Mark President, Myriad Neuroscience | Grant or award | +15,441 | 157,130 | ||
| 2021-03-24 | LANCHBURY JERRY S Chief Scientific Officer | Grant or award | +19,347 | 265,922 | ||
| 2021-03-24 | DIAZ PAUL J President and CEO | Grant or award | +159,915 | 458,869 | ||
| 2021-02-18 | Haas Kevin Richard SVP Technology | Grant or award | +10,000 | 42,443 | ||
| 2021-02-18 | Ancona Margaret SVP Enterprise Transformation | Grant or award | +30,000 | 30,000 | ||
| 2021-02-18 | Riggsbee Richard Bryan Chief Financial Officer | Returned to the company | −11,175 | $29.69 | $332K | 307,151 |
| 2021-02-16 | LANCHBURY JERRY S Chief Scientific Officer | Exercise or conversion | +74,445 | $18.00 | $1.3M | 321,020 |
| 2021-02-16 | LANCHBURY JERRY S Chief Scientific Officer | Sale | −74,445 | $29.71 | $2.2M | 246,575 |
| 2021-02-16 | LANCHBURY JERRY S Chief Scientific Officer | Exercise or conversion | +5,555 | $18.00 | $100K | 252,130 |
| 2021-02-16 | LANCHBURY JERRY S Chief Scientific Officer | Sale | −5,555 | $29.71 | $165K | 246,575 |
| 2021-02-16 | LANCHBURY JERRY S Chief Scientific Officer | Exercise or conversion · Incentive Stock Option (right to buy) | −5,555 | 0 | ||
| 2021-02-16 | LANCHBURY JERRY S Chief Scientific Officer | Exercise or conversion · Non-Qualified Stock Option (right to buy) | −74,445 | 0 | ||
| 2021-01-08 | Parkinson Paul EVP Strategy and Innovation | Sale | −11,824 | $25.00 | $296K | 76,746 |
| 2020-12-04 | Newcomer Lee Nisley Director | Grant or award | +15,889 | 27,576 | ||
| 2020-12-04 | Phanstiel S. Louise Director | Grant or award | +15,889 | 82,679 | ||
| 2020-12-04 | DREISMANN HEINRICH Director | Grant or award | +15,889 | 70,679 | ||
| 2020-12-04 | LANGER DENNIS Director | Grant or award | +15,889 | 76,679 |
Page 29 of 35 · 689 trades